On September 17, 2024, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals Inc (RXRX, Financial) at a price of $6.84 per share, as reported in the SEC Filing. Following this transaction, the insider now owns 7,109,875 shares of the company.
Recursion Pharmaceuticals Inc is a biotechnology firm that utilizes an AI-driven platform to decode biology and radically improve lives. The company is engaged in the discovery of treatments for rare genetic diseases and other conditions.
Over the past year, Blake Borgeson has sold a total of 347,623 shares and has not purchased any shares. This recent transaction continues a trend of insider sales at Recursion Pharmaceuticals Inc, with a total of 68 insider sales and no insider buys reported over the past year.
Shares of Recursion Pharmaceuticals Inc were trading at $6.84 on the day of the sale, giving the company a market cap of approximately $1.96 billion. The stock's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are calculated based on historical trading multiples, adjustments for past performance, and future business expectations.
According to the GF Value, the intrinsic value of RXRX is estimated at $12.62 per share, which suggests that the stock is currently undervalued with a price-to-GF-Value ratio of 0.54. This valuation indicates that the stock might be a possible value trap, and potential investors should think twice before making an investment decision.
This insider sale could provide current and potential shareholders with insights into how insiders view the stock's current valuation and future prospects. As always, investors should consider not only insider transactions but also other fundamental and technical aspects of the company when making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
